BioNTech’s cash and securities nearly equal its market value, meaning investors aren’t paying much for the Covid franchise and a pipeline focused on cancer treatments.

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

BioNTech SE BNTX shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current price still feels rich, this article walks through what the numbers actually ...

BioNTech (BNTX) stock is down nearly 20% at the time of writing after the German company posted a Q4 loss, issued muted guidance, and said its cofounders will depart by the end of this year CEO Uğur ...

BioNTech (BNTX) shares fell over 20% after the company reported an earnings miss and announced plans for its founders to ...

Nothing about the recent past, present, or foreseeable future seems all that compelling.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...